(I) or their pharmaceutically acceptable forms, wherein each of G, Ra, Rb, Rc and Rd has a value described in the present application, to pharmaceutical compositions, and methods of treating a FAAH-mediated condition.;EFFECT: developing the method of treating the FAAH-mediated condition.;32 cl, 22 tbl, 351 ex"/>
公开/公告号RU2539595C2
专利类型
公开/公告日2015-01-20
原文格式PDF
申请/专利权人 INFINITI FARMASJUTIKALZ INK.;
申请/专利号RU20110151635
发明设计人 BENKE MARK L. (US);KASTRO ALFREDO S. (US);CHAN LOURENS K. (US);EHVANS KEHTRIN A. (US);GRENE LUI (US);GROGAN MAJKL DZH. (US);LEBLAN IV (CA);LJU TAO (US);PELJUZO STEFAN (US);SNAJDER DEHNIEL A. (US);TIBBITTS TOMAS T. (US);
申请日2010-05-18
分类号C07D261/04;C07D413/04;C07D413/12;C07D413/14;C07D498/04;C07D498/10;A61K31/42;A61P29;A61P37/02;A61P25;
国家 RU
入库时间 2022-08-21 14:56:33